Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Soleno Therapeutics, Inc. (OTC: SLNO).

Full DD Report for SLNO

You must become a subscriber to view this report.


Recent News from (OTC: SLNO)

Soleno Therapeutics reports Q1 results
Soleno Therapeutics (NASDAQ: SLNO ): Q1 EPS of -$0.17 More news on: Soleno Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 16 2018 10:15
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial res...
Source: GlobeNewswire
Date: May, 16 2018 08:00
Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated its multi-center Phase ...
Source: GlobeNewswire
Date: May, 14 2018 08:00
INSYS launches mid-stage study of CBD in rare obesity disorder
INSYS Therapeutics ( INSY -0.7% ) initiates a Phase 2 clinical trial assessing its cannabidiol (CBD) oral solution for the potential treatment of Prader-Willi syndrome (PWS), a rare inherited disorder characterized by an insatiable appetite that leads to severe obesity. More news on: I...
Source: SeekingAlpha
Date: April, 27 2018 12:20
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial r...
Source: GlobeNewswire
Date: April, 02 2018 08:00
Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will discuss Portola Pharmaceuticals ( PTLA ), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. Portola reported that the European Medicines Agency’s ((EM...
Source: SeekingAlpha
Date: February, 21 2018 11:49
Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing nove...
Source: GlobeNewswire
Date: February, 20 2018 08:00
Daily Insider Ratings Round Up 12/19/17: BAS, GBT, PSEC, DRNA, SLNO
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: December, 21 2017 00:18
Soleno Therapeutics secures private $15M capital raise; shares up 2%
Soleno Therapeutics ( SLNO +2.3% ) inks an agreement with certain investors for the direct sale of 8,141,116 shares of common stock at $1.8425 per share yielding ~$15M in proceeds. More news on: Soleno Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: December, 12 2017 12:50
Soleno Therapeutics Announces $15 Million Private Placement
Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
Source: GlobeNewswire
Date: December, 12 2017 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-142.562.65662.65662.4710,767
2018-08-132.672.552.702.531117,020
2018-08-102.582.702.712.50139,750
2018-08-092.682.542.682.51123,343
2018-08-082.712.652.72692.587,148

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on SLNO.


About Soleno Therapeutics, Inc. (OTC: SLNO)

Logo for Soleno Therapeutics, Inc. (OTC: SLNO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $18,604,196 - 03/21/2018
  • Issue and Outstanding: 10,002,256 - 11/09/2017

 


Recent Filings from (OTC: SLNO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 02 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 16 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: February, 08 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (OTC: SLNO)

Daily Technical Chart for (OTC: SLNO)


Stay tuned for daily updates and more on (OTC: SLNO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SLNO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SLNO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SLNO and does not buy, sell, or trade any shares of SLNO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/